To help overcome that obstacle, researchers from MIT and Massachusetts General Hospital have now developed a small, implantable device that delivers chemotherapy drugs directly to pancreatic tumors.In a study of mice, they found that this approach was up to 12 times more effective than giving chemotherapy drugs by intravenous injection, which is how most pancreatic cancer patients are treated.
In hopes that getting drugs directly to the tumor site would improve treatment, the researchers engineered a flexible polymer film that is made from a polymer called PLGA, which is widely used for drug delivery and other medical applications.The film can be rolled into a narrow tube and inserted through a catheter, so surgically implanting it is relatively simple.Once the film reaches the pancreas, it unfolds and conforms to the shape of the tumor.
Drugs are embedded into the film and then released over a preprogrammed period of time.The film is designed so that the drug is only secreted from the side in contact with the tumor, minimizing side effects on nearby organs.
“The greatest benefit of this device is the ability to implant it with minimally invasive procedures so we can give a tool to oncologists and surgeons to reach tumors that otherwise would be difficult to reach,” Indolfi says.
While they began this project with a focus on pancreatic cancer, they expect that this approach could also be useful in treating other tumors that are difficult to reach, such as tumors of the gastrointestinal tract.
Near-infrared photoimmunotherapy uses an antibody–photoabsorber conjugate that binds to cancer cells. When near-infrared light is applied, the cells swell and then burst, causing the cancer cell to die. Photoimmunotherapy is in clinical trials in patients with inoperable tumors.
A. 目はよくカメラに例えられますが、目の奥にはカメラのフィルムにあたる網膜と呼ばれる場所があります。外から目に入った光は網膜でうけとられ、その情報が神経節細胞と呼ばれる神経を通じて脳に伝わり、ものが見えます。緑内障ではこの神経が徐々に失われていくため、視野が狭くなったり視力が低下したりします。神経節細胞は目と脳を結ぶ神経で、一つの細胞の長さが約10cmと非常に長いのが特徴です。これは、一般的な細胞(数十ミクロン)の100倍以上の長さです。iPS細胞を用いた再生を考えた場合、このような巨大な構造を再生することは現時点では難しいと考えられています。したがって、緑内障に再生医療を適用しようとする研究は現段階ではあまり行われていないと思います。